Evidence map›Paper›PMID 36203030›Full record

ArticleCommunications biology2022

A framework for dissecting affinities of multidrug efflux transporter AcrB to fluoroquinolones.

Julia Vergalli, Hugo Chauvet, Francesco Oliva, Jelena Pajović, Giuliano Malloci, Attilio Vittorio Vargiu, Matthieu Réfrégiers, Paolo Ruggerone, Jean-Marie Pagès

Abstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Potato (Molecules (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Efflux-Mediated Resistance inAntibiotics (Basel, Switzerland) · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Julia Vergalli *UMR_MD1, U-1261, Aix-Marseille Univ, INSERM, IRBA, MCT, Marseille, France.
Hugo Chauvet *DISCO beamline, Synchrotron Soleil, Saint-Aubin, France.
Francesco Oliva *Department of Physics, University of Cagliari, 09042, Monserrato, (CA), Italy.ORCID 0000-0002-6734-5308
Jelena PajovićDISCO beamline, Synchrotron Soleil, Saint-Aubin, France.
Giuliano MallociDepartment of Physics, University of Cagliari, 09042, Monserrato, (CA), Italy.ORCID 0000-0002-5985-257X
Attilio Vittorio VargiuDepartment of Physics, University of Cagliari, 09042, Monserrato, (CA), Italy.ORCID 0000-0003-4013-8867
Matthieu RéfrégiersDISCO beamline, Synchrotron Soleil, Saint-Aubin, France.ORCID 0000-0002-3281-2308
Paolo RuggeroneDepartment of Physics, University of Cagliari, 09042, Monserrato, (CA), Italy.ORCID 0000-0003-0825-0824
Jean-Marie PagèsUMR_MD1, U-1261, Aix-Marseille Univ, INSERM, IRBA, MCT, Marseille, France. Jean-Marie.PAGES@univ-amu.fr.ORCID 0000-0001-7092-7977

Funding

Optimization of efflux avoidance and inhibition for antibiotic developmentR01AI136799 · NIAID · UNIVERSITY OF OKLAHOMA · PI GNANAKARAN, SANDRASEGARAM, RUGGERONE, PAOLO · 2018 to 2022
$5.7M
NIAID NIH HHS R01 AI136799
6 · The paper itself

Abstract

Sufficient concentration of antibiotics close to their target is key for antimicrobial action. Among the tools exploited by bacteria to reduce the internal concentration of antibiotics, multidrug efflux pumps stand out for their ability to capture and expel many unrelated compounds out of the cell. Determining the specificities and efflux efficiency of these pumps towards their substrates would provide quantitative insights into the development of antibacterial strategies. In this light, we developed a competition efflux assay on whole cells, that allows measuring the efficacy of extrusion of clinically used quinolones in populations and individual bacteria. Experiments reveal the efficient competitive action of some quinolones that restore an active concentration of other fluoroquinolones. Computational methods show how quinolones interact with the multidrug efflux transporter AcrB. Combining experiments and computations unveils a key molecular mechanism acting in vivo to detoxify bacterial cells. The developed assay can be generalized to the study of other efflux pumps.

Indexed as

Escherichia coli ProteinsFluoroquinolonesAnti-Bacterial AgentsATP-Binding Cassette, Sub-Family C ProteinsDrug Resistance, Multiple, BacterialMembrane Transport ProteinsAnti-Bacterial AgentsATP-Binding Cassette, Sub-Family C ProteinsEscherichia coli ProteinsFluoroquinolonesMembrane Transport Proteins

Identifiers

PMID36203030
PMCPMC9537517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.